|
Annexon, Inc. (Annx) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Annexon, Inc. (ANNX) Bundle
Mit unserem DCF-Taschenrechner, der für die Genauigkeit entwickelt wurde, können Sie die Bewertung von Annexon, Inc. unter Verwendung realer Finanzinformationen bewerten und vollständige Flexibilität bieten, um alle wesentlichen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -32.0 | -62.8 | -128.6 | -143.5 | -141.6 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .5 | .7 | 3.4 | 3.3 | 2.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -32.5 | -63.5 | -132.0 | -146.8 | -143.7 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 43.9 | 351.2 | 242.7 | 242.7 | 259.7 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.4 | 3.7 | 11.2 | 7.4 | 5.5 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.3 | -.5 | -1.7 | -6.5 | -.2 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -32.5 | -62.8 | -129.4 | -143.0 | -143.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -30.0 | -61.2 | -120.2 | -150.0 | -143.7 | -5.5 | .0 | .0 | .0 | .0 |
| WACC, % | 8.42 | 8.41 | 8.41 | 8.4 | 8.42 | 8.41 | 8.41 | 8.41 | 8.41 | 8.41 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -5 | |||||||||
| Net Debt | -194 | |||||||||
| Equity Value | 189 | |||||||||
| Diluted Shares Outstanding, MM | 76 | |||||||||
| Equity Value Per Share | 2.49 |
What You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled real ANNX financials.
- Accurate Data: Historical figures and forward-looking projections (as indicated in the highlighted cells).
- Flexible Forecasting: Modify forecast parameters such as revenue growth, EBITDA %, and WACC.
- Instant Calculations: Quickly observe how your inputs affect Annexon’s valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for clarity and ease of use, complete with step-by-step guidance.
Key Features
- 🔍 Real-Life ANNX Financials: Pre-filled historical and projected data for Annexon, Inc. (ANNX).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Annexon’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Annexon’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Get the pre-configured Excel file featuring Annexon, Inc.'s (ANNX) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and compare results instantly.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose Annexon, Inc. (ANNX)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Expertise: A team of experienced professionals with a strong track record in neuroscience.
- Robust Pipeline: A diverse range of candidates in various stages of development.
- Commitment to Patients: Focused on improving the lives of those affected by neurodegenerative diseases.
- Strong Partnerships: Collaborations with leading research institutions and organizations enhance our capabilities.
Who Should Use This Product?
- Investors: Accurately estimate Annexon, Inc.'s (ANNX) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Annexon, Inc. (ANNX).
- Consultants: Efficiently customize the template for valuation reports tailored to Annexon, Inc. (ANNX) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like Annexon, Inc. (ANNX).
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to Annexon, Inc. (ANNX).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Annexon, Inc. (ANNX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Annexon, Inc. (ANNX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.